Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Aura Biosciences Inc ( (AURA) ) is now available.
On March 30, 2026, Aura Biosciences reported fourth-quarter and full-year 2025 results, highlighting continued progress across its bel-sar oncology pipeline and solid financial resources. The company ended 2025 with $144.2 million in cash, cash equivalents and marketable securities, which it expects will fund operations into the first quarter of 2027, while annual net loss widened to $106.2 million driven mainly by higher R&D spending on its global Phase 3 program.
The Phase 3 CoMpass trial in early choroidal melanoma accelerated enrollment in 2025, supporting guidance for enrollment completion by mid-2026 and topline data in the second half of 2027, reinforcing Aura’s bid to establish bel-sar as a first frontline vision-preserving therapy in this indication. Across its expansion programs, Aura advanced a Phase 1b/2 trial in non-muscle invasive bladder cancer with initial three-month data expected mid-2026, achieved 12-month stability for a new non-ocular tumor formulation aimed at in-office urologic use, and maintained timelines for early proof-of-concept data in metastases to the choroid and ocular surface cancers in 2026, underscoring a broadening solid tumor franchise despite ongoing clinical and regulatory risks inherent to its development-stage portfolio.
The most recent analyst rating on (AURA) stock is a Sell with a $5.50 price target. To see the full list of analyst forecasts on Aura Biosciences Inc stock, see the AURA Stock Forecast page.
Spark’s Take on AURA Stock
According to Spark, TipRanks’ AI Analyst, AURA is a Neutral.
The score is driven primarily by weak financial performance: no revenue, increasing losses, and significant ongoing cash burn despite relatively low leverage. Technicals add further pressure with the stock trading below major moving averages and a negative MACD, while valuation metrics offer limited support due to the negative P/E and no dividend yield.
To see Spark’s full report on AURA stock, click here.
More about Aura Biosciences Inc
Aura Biosciences Inc. is a Boston-based, clinical-stage biotechnology company developing precision therapies for solid tumors with an emphasis on preserving organ function. Its lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and in early-stage development for additional ocular oncology indications and bladder cancer, targeting high unmet medical needs in ocular and urologic oncology.
Average Trading Volume: 225,028
Technical Sentiment Signal: Hold
Current Market Cap: $398.2M
See more insights into AURA stock on TipRanks’ Stock Analysis page.